Literature DB >> 20439986

3BP2 adapter protein is required for receptor activator of NFκB ligand (RANKL)-induced osteoclast differentiation of RAW264.7 cells.

Amel GuezGuez1, Virginie Prod'homme, Xavier Mouska, Alice Baudot, Claudine Blin-Wakkach, Robert Rottapel, Marcel Deckert.   

Abstract

The adapter protein 3BP2 (also known as SH3BP2 and Abl SH3-binding protein 2) has been involved in leukocyte signaling and activation downstream immunoreceptors. Genetic studies have further associated 3BP2 mutations to the human disease cherubism and to inflammation and bone dysfunction in mouse. However, how wild type 3BP2 functions in macrophage differentiation remains poorly understood. In this study, using small interfering RNA-mediated silencing of 3BP2 in the RAW264.7 monocytic cell line, we show that 3BP2 was required for receptor activator of NFkappaB ligand (RANKL)-induced differentiation of RAW264.7 cells into multinucleated mature osteoclasts but not for granulocyte macrophage-colony stimulating factor/interleukin-4-induced differentiation into dendritic cells. 3BP2 silencing was associated with impaired activation of multiple signaling events downstream of RANK, including actin reorganization; Src, ERK, and JNK phosphorylation; and up-regulation of osteoclastogenic factors. In addition, 3BP2 knockdown cells induced to osteoclast by RANKL displayed a reduced increase of Src and nuclear factor of activated T cells (NFATc1) mRNA and protein expression. Importantly, 3BP2 interacted with Src, Syk, Vav, and Cbl in monocytic cells, and the introduction of constitutively active mutants of Src and NFATc1 in 3BP2-deficient cells restored osteoclast differentiation. Finally, the expression of a 3BP2 cherubism mutant was found to promote increased Src activity and NFAT-dependent osteoclast formation. Together, this study demonstrates that wild type 3BP2 is a key regulator of RANK-mediated macrophage differentiation into osteoclast through Src and NFATc1 activation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20439986      PMCID: PMC2898328          DOI: 10.1074/jbc.M109.091124

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  51 in total

1.  Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals.

Authors:  Masahiro Shinohara; Takako Koga; Kazuo Okamoto; Shinya Sakaguchi; Kimiko Arai; Hisataka Yasuda; Toshiyuki Takai; Tatsuhiko Kodama; Tomohiro Morio; Raif S Geha; Daisuke Kitamura; Tomohiro Kurosaki; Wilfried Ellmeier; Hiroshi Takayanagi
Journal:  Cell       Date:  2008-03-07       Impact factor: 41.582

Review 2.  Actin cytoskeletal organisation in osteoclasts: a model to decipher transmigration and matrix degradation.

Authors:  Frédéric Saltel; Anne Chabadel; Edith Bonnelye; Pierre Jurdic
Journal:  Eur J Cell Biol       Date:  2008-02-21       Impact factor: 4.492

3.  DAP12 couples c-Fms activation to the osteoclast cytoskeleton by recruitment of Syk.

Authors:  Wei Zou; Jennifer L Reeve; Yuli Liu; Steven L Teitelbaum; F Patrick Ross
Journal:  Mol Cell       Date:  2008-08-08       Impact factor: 17.970

Review 4.  Rho GTPases in osteoclasts: orchestrators of podosome arrangement.

Authors:  Stéphane Ory; Hélène Brazier; Géraldine Pawlak; Anne Blangy
Journal:  Eur J Cell Biol       Date:  2008-04-23       Impact factor: 4.492

5.  The p85alpha subunit of class IA phosphatidylinositol 3-kinase regulates the expression of multiple genes involved in osteoclast maturation and migration.

Authors:  Veerendra Munugalavadla; Sasidhar Vemula; Emily Catherine Sims; Subha Krishnan; Shi Chen; Jincheng Yan; Huijie Li; Paul J Niziolek; Clifford Takemoto; Alexander G Robling; Feng-Chun Yang; Reuben Kapur
Journal:  Mol Cell Biol       Date:  2008-09-22       Impact factor: 4.272

6.  The Src family kinase, Lyn, suppresses osteoclastogenesis in vitro and in vivo.

Authors:  Hyun-Ju Kim; Kaihua Zhang; Lihong Zhang; F Patrick Ross; Steven L Teitelbaum; Roberta Faccio
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-26       Impact factor: 11.205

7.  Spleen tyrosine kinase functions as a tumor suppressor in melanoma cells by inducing senescence-like growth arrest.

Authors:  Olivier Bailet; Nina Fenouille; Patricia Abbe; Guillaume Robert; Stéphane Rocchi; Nadège Gonthier; Christophe Denoyelle; Michel Ticchioni; Jean-Paul Ortonne; Robert Ballotti; Marcel Deckert; Sophie Tartare-Deckert
Journal:  Cancer Res       Date:  2009-03-17       Impact factor: 12.701

8.  SH3BP2 is an activator of NFAT activity and osteoclastogenesis.

Authors:  Steven A Lietman; Lihong Yin; Michael A Levine
Journal:  Biochem Biophys Res Commun       Date:  2008-04-25       Impact factor: 3.575

9.  NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism.

Authors:  Antonios O Aliprantis; Yasuyoshi Ueki; Rosalyn Sulyanto; Arnold Park; Kirsten S Sigrist; Sudarshana M Sharma; Michael C Ostrowski; Bjorn R Olsen; Laurie H Glimcher
Journal:  J Clin Invest       Date:  2008-10-09       Impact factor: 14.808

Review 10.  The role of NFAT in osteoclast formation.

Authors:  Hiroshi Takayanagi
Journal:  Ann N Y Acad Sci       Date:  2007-11       Impact factor: 5.691

View more
  15 in total

1.  Investigating global gene expression changes in a murine model of cherubism.

Authors:  Tulika Sharma; Justin Cotney; Vijender Singh; Archana Sanjay; Ernst J Reichenberger; Yasuyoshi Ueki; Peter Maye
Journal:  Bone       Date:  2020-03-10       Impact factor: 4.398

2.  Cloning and characterization of the human SH3BP2 promoter.

Authors:  Chun Fan; Robert J Gaivin; Thomas A Marth; Belinda Willard; Michael A Levine; Steven A Lietman
Journal:  Biochem Biophys Res Commun       Date:  2012-07-17       Impact factor: 3.575

Review 3.  RNA therapeutics targeting osteoclast-mediated excessive bone resorption.

Authors:  Yuwei Wang; David W Grainger
Journal:  Adv Drug Deliv Rev       Date:  2011-09-10       Impact factor: 15.470

4.  Decreased SH3BP2 inhibits osteoclast differentiation and function.

Authors:  Teruya Kawamoto; Chun Fan; Robert J Gaivin; Michael A Levine; Steven A Lietman
Journal:  J Orthop Res       Date:  2011-03-29       Impact factor: 3.494

5.  3BP2-deficient mice are osteoporotic with impaired osteoblast and osteoclast functions.

Authors:  Noam Levaot; Paul D Simoncic; Ioannis D Dimitriou; Andrew Scotter; Jose La Rose; Adeline H M Ng; Thomas L Willett; Chiachien J Wang; Salima Janmohamed; Marc Grynpas; Ernst Reichenberger; Robert Rottapel
Journal:  J Clin Invest       Date:  2011-07-18       Impact factor: 14.808

6.  The adaptor 3BP2 is required for KIT receptor expression and human mast cell survival.

Authors:  Erola Ainsua-Enrich; Eva Serrano-Candelas; Damiana Álvarez-Errico; César Picado; Joan Sayós; Juan Rivera; Margarita Martín
Journal:  J Immunol       Date:  2015-03-25       Impact factor: 5.422

7.  Cherubism allele heterozygosity amplifies microbe-induced inflammatory responses in murine macrophages.

Authors:  Virginie Prod'Homme; Laurent Boyer; Nicholas Dubois; Aude Mallavialle; Patrick Munro; Xavier Mouska; Isabelle Coste; Robert Rottapel; Sophie Tartare-Deckert; Marcel Deckert
Journal:  J Clin Invest       Date:  2015-02-23       Impact factor: 14.808

8.  Loss of SH3 domain-binding protein 2 function suppresses bone destruction in tumor necrosis factor-driven and collagen-induced arthritis in mice.

Authors:  Tomoyuki Mukai; Richard Gallant; Shu Ishida; Mizuho Kittaka; Teruhito Yoshitaka; David A Fox; Yoshitaka Morita; Keiichiro Nishida; Robert Rottapel; Yasuyoshi Ueki
Journal:  Arthritis Rheumatol       Date:  2015-03       Impact factor: 10.995

9.  SH3BP2 cherubism mutation potentiates TNF-α-induced osteoclastogenesis via NFATc1 and TNF-α-mediated inflammatory bone loss.

Authors:  Tomoyuki Mukai; Shu Ishida; Remi Ishikawa; Teruhito Yoshitaka; Mizuho Kittaka; Richard Gallant; Yi-Ling Lin; Robert Rottapel; Marco Brotto; Ernst J Reichenberger; Yasuyoshi Ueki
Journal:  J Bone Miner Res       Date:  2014-12       Impact factor: 6.741

Review 10.  The role of SH3BP2 in the pathophysiology of cherubism.

Authors:  Ernst J Reichenberger; Michael A Levine; Bjorn R Olsen; Maria E Papadaki; Steven A Lietman
Journal:  Orphanet J Rare Dis       Date:  2012-05-24       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.